{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,8,21]],"date-time":"2023-08-21T04:59:07Z","timestamp":1692593947969},"reference-count":41,"publisher":"Wiley","issue":"S1","license":[{"start":{"date-parts":[[2023,6,14]],"date-time":"2023-06-14T00:00:00Z","timestamp":1686700800000},"content-version":"vor","delay-in-days":13,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accp1.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Clinical Pharma"],"published-print":{"date-parts":[[2023,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Pharmacokinetic (PK) studies in pregnant, postpartum, and breastfeeding people are critical to informing appropriate medication use and dosing. A key component of translating PK results in these complex populations into clinical practice involves the systematic review and interpretation of data by guideline panels, composed of clinicians, scientists, and community members, to leverage available data for informed decision making by clinicians and patients and offer clinical best practices. Interpretation of PK data in pregnancy involves evaluation of multiple factors such as the study design, target population, and type of sampling performed. Assessments of fetal and infant drug exposure while in utero or during breastfeeding, respectively, are also critical for informing whether medications are safe to use during pregnancy and throughout postpartum in lactating people. This review will provide an overview of this translational process, discussion of the various factors considered by guideline panels, and practical aspects of implementing certain recommendations, using the HIV field as an example.<\/jats:p>","DOI":"10.1002\/jcph.2240","type":"journal-article","created":{"date-parts":[[2023,6,15]],"date-time":"2023-06-15T05:01:21Z","timestamp":1686805281000},"update-policy":"http:\/\/dx.doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Translating Clinical Pharmacology Data in Pregnancy to Evidence\u2010Based Guideline Recommendations: Perspectives From the HIV Field"],"prefix":"10.1002","volume":"63","author":[{"given":"Kristina M.","family":"Brooks","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Sciences University of Colorado Anschutz Medical Campus  Aurora Colorado USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachel K.","family":"Scott","sequence":"additional","affiliation":[{"name":"Division of Women's Health Research MedStar Health Research Institute  Washington District of Columbia USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brookie M.","family":"Best","sequence":"additional","affiliation":[{"name":"Skaggs School of Pharmacy and Pharmaceutical Sciences University of California San Diego  San Diego California USA"},{"name":"Pediatrics Department University of California San Diego School of Medicine\u2010Rady Children's Hospital San Diego  San Diego California USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edmund","family":"Capparelli","sequence":"additional","affiliation":[{"name":"Skaggs School of Pharmacy and Pharmaceutical Sciences University of California San Diego  San Diego California USA"},{"name":"Pediatrics Department University of California San Diego School of Medicine\u2010Rady Children's Hospital San Diego  San Diego California USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeremiah D.","family":"Momper","sequence":"additional","affiliation":[{"name":"Skaggs School of Pharmacy and Pharmaceutical Sciences University of California San Diego  San Diego California USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2023,6,14]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002160"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz121"},{"key":"e_1_2_9_4_1","unstructured":"Panel on Treatment of HIV During Pregnancy and Prevention of Perinatal Transmission. Recommendations for the Use of Antiretroviral Drugs During Pregnancy and Interventions to Reduce Perinatal HIV Transmission in the United States. Department of Health and Human Services. Year. Accessed 17 Feb 2023https:\/\/clinicalinfo.hiv.gov\/en\/guidelines\/perinatal"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2048"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000002597"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1905230"},{"key":"e_1_2_9_8_1","unstructured":"PatelP ThiagarajahS FordS et\u00a0al.Cabotegravir pharmacokinetic tail in pregnancy and neonatal outcomes[Abstract 775].Conference on Retroviruses and Opportunistic Infections. Boston MA;2020."},{"key":"e_1_2_9_9_1","unstructured":"Delany\u2010MoretlweS GuoX HanscomB et\u00a0al.Evaluation of CAB\u2010LA safety and PK in pregnant women in the blinded phase of HPTN 084.Conference on Retroviruses and Opportunistic Infections. Virtual;2022."},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1097\/AOG.0000000000002633"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.114.009029"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.ackd.2013.01.012"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ijo.0801631"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000001992"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000002856"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000002857"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000002767"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12078"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2021.721059"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1093\/ajcn\/85.1.182"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1080\/16070658.2009.11734213"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.167"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000001755"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e32834a1dd9"},{"issue":"1","key":"e_1_2_9_25_1","first-page":"121","article-title":"The effect of pregnancy on the pharmacokinetics of total and unbound dolutegravir and its main metabolite in women living with human immunodeficiency virus","volume":"72","author":"Bollen P","year":"2021","journal-title":"Clin Infect Dis"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002895"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1155\/2011\/783528"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13432"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000002261"},{"key":"e_1_2_9_30_1","unstructured":"Darunavir (Prezista) Clinical Pharmacology and Biopharmaceutics Review. Center for Drug Evaluation and Research. U.S. Food and Drug Administration (2005)."},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-017-0184-8"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cix534"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000000968"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000002163"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa488"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e3181d6c9ed"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dku367"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000002637"},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkab424"},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000003032"},{"key":"e_1_2_9_41_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000002830"},{"key":"e_1_2_9_42_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2013-1985"}],"container-title":["The Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jcph.2240","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,20]],"date-time":"2023-08-20T03:44:55Z","timestamp":1692503095000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1002\/jcph.2240"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":41,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["10.1002\/jcph.2240"],"URL":"https:\/\/doi.org\/10.1002\/jcph.2240","archive":["Portico"],"relation":{},"ISSN":["0091-2700","1552-4604"],"issn-type":[{"value":"0091-2700","type":"print"},{"value":"1552-4604","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"2022-11-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-03-28","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-06-14","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}